Table 1.
Patients and disease characteristics.
| Variable | N | ||
|---|---|---|---|
| Patient-related | |||
| Sex, male, n (%) | 240 | 144 (60.0%) | |
| Age at CML diagnosis (yrs), median (range) | 240 | 45 (13–86) | |
| Age at onset of CML-BP (yrs), median (range) | 240 | 49 (18–86) | |
| Phase at diagnosis, n (%) | CML-CP | 240 | 151 (62.9%) |
| CML-BP | 89 (37.0%) | ||
| Onset of CML-BP after diagnosis of CML-CP (mo), median (range) | 151 | 29.1 (0.1–378) | |
| ELTS Score at diagnosis of CML-CP, n (%) | Low risk, n (%) | 151 | 36 (39.6%) |
| Intermediate risk, n (%) | 33 (36.3%) | ||
| High risk, n (%) | 22 (24.2%) | ||
| CML-related | |||
| Morphology of CML-BP | Myeloid | 233 | 117 (50.2%) |
| Lymphoid | 71 (30.5%) | ||
| Mixed | 10 (4.3%) | ||
| Megakaryoblastic | 3 (1.3%) | ||
| Unknown | 32 (13.7%) | ||
| Not reported | 7 | ||
| Additional chromosomal abnormalities (ACAs) at onset of CML-BP, yes, n (%) | Complex karyotype | 174 | 52 (29.9%) |
| Chr. 3q26.2 rearrangements | 9 (5.2%) | ||
| −7/−7q | 12 (6.9%) | ||
| +8 | 23 (13.2%) | ||
| +Ph | 20 (11.5%) | ||
| Others | 50 (28.7%) | ||
| Not reported | 66 | ||
| High risk ACAsa, yes, n (%) | 174 | 72 (41.4%) | |
| Not reported | 66 | ||
| CNS involvement, yes, n (%) | 214 | 21 (9.8%) | |
| Not reported | 26 | ||
| Extramedullary disease, yes, n (%) | 220 | 43 (19.5%) | |
| Not reported | 20 | ||
M male, F female, CML chronic myeloid leukemia, yrs years, CML-BP chronic myeloid leukemia blast phase, CML-CP chronic myeloid leukemia chronic phase, mo months, ELTS EUTOS long term survival, chr. chromosome, CNS central nervous system.
aHigh risk ACAs: +8, +Ph, i[17q], +17, +19, +21, 11q23 and 3q26.2 rearrangements, −7/−7q abnormalities, complex karyotype.